

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/445, A61P 25/06	A1	(11) International Publication Number: WO 00/21534 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/GB99/03398 (22) International Filing Date: 13 October 1999 (13.10.99) (30) Priority Data: 9822333.2 13 October 1998 (13.10.98) GB (71) Applicants (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). WOELM PHARMA GMBH & CO. [DE/DE]; Rhoendorfer Strasse 80, D-53587 Bad Honnef (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): MANN, Stephen, G. [GB/GB]; J. & J. - M.S.D., Enterprise House, Station Road, Loudwater, High Wycombe, Buckinghamshire HP10 9UF (GB). SCHIRMER, Gudola [DE/DE]; Kurt-Schumacher-Ring 72, D-63303 Dreieich (DE). (74) Agent: HORGAN, James; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMBINATION OF IBUPROFEN-LYSINE AND DOMPERIDONE FOR TREATING MIGRAINE (57) Abstract <p>The present invention relates to a combination of ibuprofen lysine and domperidone for treating and/or preventing migraine, migraine-associated nausea and vomiting and headache with nausea following overindulgence.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL COMBINATION OF IBUPROFEN-LYSINE
AND DOMPERIDONE FOR TREATING MIGRAINE

The present invention relates to a pharmaceutical composition comprising a combination of active ingredients. More particularly, the invention concerns a pharmaceutical formulation comprising ibuprofen lysinate in combination with domperidone or a salt thereof, for use in the control of migraine, and in particular migraine-associated nausea and vomiting, and of headache with nausea following overindulgence.

Migraine is a recurrent, often familial, symptom complex of periodic attacks of vascular headache, which is frequently associated with nausea and vomiting. Migraine affects approximately 17% of adult women and 6% of adult men (Stewart *et al.*, *Neurology*, 1994, 44 (suppl. 4), 517-523).

Ibuprofen, or (\pm)-2-(*p*-isobutylphenyl)propionic acid, is a well-known non-steroidal anti-inflammatory drug (NSAID) of the formula



The compound is widely prescribed for its analgesic and anti-pyretic activity. It is also available as a low dose over-the-counter product to be used orally for the treatment of minor aches and pains, and as a topically applied gel for the treatment of muscular sprains and strains.

The lysine salt of ibuprofen has been developed in order to confer water solubility upon the compound, primarily to assist in the development of an injectable form of ibuprofen. Thus, for example, UK Patent Specification No. 1,471,910 (published 27th April 1977) describes the lysine salt of ibuprofen and its formulation as injectable solutions, tablets, freeze-dried in vials on a mannitol support, ampoules, capsules, suppositories and ointments for local applications.

Clinical experience suggests that, amongst all the available modes of administration, patients find that orally administered medicaments are the simplest to use. However, the efficacy of drugs given orally to relieve migraine attacks is not always reliable as gastrointestinal motility is inhibited even in the earliest stages of an attack, and there is always a risk of nausea during the attack culminating in vomiting.

It has now been found that these disadvantages can be overcome by the co-administration of a ibuprofen lysinate in conjunction with domperidone or a pharmaceutically acceptable salt thereof, the resulting combined formulation displaying beneficial effects in controlling migraine-associated nausea and vomiting and in headache and nausea associated with overindulgence.

Domperidone has an antinauseant effect through an action at the chemoreceptor trigger zone. It also has a gastric prokinetic effect through an action on gut dopaminergic receptors. Gastric stasis is a feature of migraine attacks and can also contribute to nausea experienced after an excess of alcohol consumption. It is also possible that domperidone will increase the absorption of the ibuprofen lysine through counteracting gastric stasis.

Ibuprofen lysinate provides rapid absorption of racemic ibuprofen because the lysine salt is very soluble. Thus this compound is particularly well suited to treatment of headache in migraine and overindulgence where drug absorption may be compromised.

Despite the above-mentioned advantageous properties of the compounds used in the present invention, their combination has been nowhere suggested in the prior art. Further the combination is surprisingly effective in providing a fast-acting anti-nauseant medication for the treatment of migraine-associated nausea and vomiting and of headache with nausea following overindulgence.

Furthermore, as both compounds are well known the combination has the advantage of being unexpectedly efficacious and safe for self

medication without medical supervision. This overcomes the long standing problem of the lack of effective self administered migraine and overindulgence medications which usually consist of an analgesic alone and thus suffer from the above-mentioned drawbacks.

5 The present invention accordingly provides a method for the treatment and/or prevention of migraine which comprises administering to a patient in need of such treatment, simultaneously, separately or sequentially, an effective amount of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof.

10 The present invention also provides a method for the treatment and/or prevention of migraine-associated nausea and vomiting or of headache with nausea following overindulgence, which comprises administering to a patient in need of such treatment, simultaneously, separately or sequentially, an effective amount of a combination of
15 ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof.

 The present invention also provides the use of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or
20 prevention of migraine.

 The present invention further provides the use of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of migraine-associated nausea and vomiting or of headache
25 with nausea following overindulgence.

 In another aspect, the present invention provides a pharmaceutical composition comprising ibuprofen lysinate in association with domperidone or a pharmaceutically acceptable salt thereof.

 In a further aspect, the present invention provides a product
30 comprising ibuprofen lysinate and domperidone or a pharmaceutically

acceptable salt thereof as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of migraine.

In a yet further aspect, the present invention provides a product comprising ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of migraine-associated nausea and vomiting or of headache with nausea following overindulgence.

In the normal practice of the invention, ibuprofen lysinate and domperidone or its pharmaceutically acceptable salt will usually be administered to a patient within a reasonable period of time, which will typically be up to about one hour apart. The compounds may be in the same pharmaceutical carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers and administered simultaneously, by mixing the materials just prior to administration. They may alternatively be in different dosage forms which can be taken simultaneously, or administered sequentially.

As is evident from its chemical name, ibuprofen is a racemic mixture. The active enantiomer of ibuprofen is the *S*(+) enantiomer. Whilst the present invention refers in general to the racemate it will be appreciated that the *S*(+) enantiomer of ibuprofen in the form of its lysine salt may be used in the same manner. A particularly convenient method for the formation and resolution of (*S*)-ibuprofen-(*S*)-lysine is described in US Patent No. 4,994,604 (published 19th February 1991).

It will also be appreciated that the lysine may exist in its racemic form or as single enantiomers. Whilst the present invention refers in general to the racemate it will be appreciated that either enantiomer, such as the naturally occurring *S*(+) enantiomer (i.e. the *laevo* (L) form), may be used in the same manner.

The pharmaceutical composition according to the present invention may conveniently be adapted for administration orally, rectally or

parenterally. For oral administration, the formulation may be presented in the form of tablets, pills, capsules, powders or granules; for parenteral administration, sterile parenteral solutions or suspensions may conveniently be utilised; and for rectal administration, the formulation
5 may conveniently be in the form of suppositories. Suitably, the pharmaceutical compositions in accordance with the invention may be presented in the form of a kit of parts adapted for simultaneous, separate or sequential administration.

The compositions may be formulated by conventional methods well
10 known in the pharmaceutical art, for example as described in *Remington: The Science and Practice of Pharmacy*, Mack Publishing Company, 19th Edition, 1995.

For administration in combination, the ibuprofen lysinate and the domperidone or its pharmaceutically acceptable salt may be presented in a
15 ratio which is consistent with the manifestation of the desired effect. In particular, the molar ratio of ibuprofen lysinate to domperidone or its pharmaceutically acceptable salt will suitably be approximately 1 to 1. Preferably, this ratio will be between 0.001 to 1 and 1000 to 1, and especially from 0.01:1 to 100:1.

20 For co-administration with domperidone or a pharmaceutically acceptable salt thereof in the treatment of migraine, and in particular migraine-associated nausea and vomiting or overindulgence, ibuprofen lysinate may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about
25 0.01 to 50 mg/kg, and especially about 0.05 to 10 mg/kg. For co-administration with ibuprofen lysinate in the treatment of migraine, and in particular migraine-associated nausea and vomiting or overindulgence, domperidone or a pharmaceutically acceptable salt thereof may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically
30 about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg and

especially about 0.05 to 10 mg/kg. The active ingredients will typically be co-administered on a regimen of 1 to 4 times per day.

A sample treatment regime based upon a tablet containing 10 mg of domperidone and 342 mg of ibuprofen lysinate (equivalent to 200 mg of
5 ibuprofen) is as follows:

for migraine - two tablets at the beginning of an attack with a dosage repeat after four hours if necessary up to a maximum of four dosages in twenty-four hours;

for overindulgence - one or two tablets at the beginning of an attack
10 repeated after four hours if necessary up to a maximum of eight tablets in one day.

The following non-limiting Example serves to illustrate the present invention.

15 EXAMPLE 1

1,000 tablets were prepared as follows:

Blending:

20

Ibuprofen lysinate, compacted and Domperidone are pre-blended by hand in a pan.

Polyvidon K 29/32 and microcrystalline cellulose are added and
25 hand-blended.

Magnesium stearate is then added and hand-blended.

The mix is finally blended in a 3,5 l-cubemixer for 30 minutes to obtain the
30 final mix.

Compressing:

The final mix is compressed to obtain round, flat tablets of 13 mm diameter and 409 mg weight, using a Korsch KO excenter tablet press.

5

Formula per tablet:

Ibuprofen lysinate, compacted	342.0 mg
Domperidone	10.0 mg
Polyvidon K 29/32	17.0 mg
Microcrystalline Cellulose	36.0 mg
Magnesium Stearate	4.0 mg
	<hr/> 409.0 mg <hr/>

10 The microcrystalline cellulose may be Avicel PH102. The magnesium stearate is generally from a vegetal source. In addition to the above ingredients about 4mg talc may be added to the mixture. Lactose fast flow may also be added.

The tablets may be supplied with a film coating comprising hypromellose, hydroxypropylcellulose, titanium dioxide and water.

15

CLAIMS:

1. A pharmaceutical composition comprising ibuprofen lysinate
in association with domperidone or a pharmaceutically acceptable salt
5 thereof.
2. A product comprising ibuprofen lysinate and domperidone or
a pharmaceutically acceptable salt thereof as a combined preparation for
simultaneous, separate or sequential administration.
10
3. The use of a combination of ibuprofen lysinate and
domperidone or a pharmaceutically acceptable salt thereof for the
manufacture of a medicament for the treatment and/or prevention of
migraine.
15
4. The use of a combination of ibuprofen lysinate and
domperidone or a pharmaceutically acceptable salt thereof for the
manufacture of a medicament for the treatment and/or prevention of
migraine-associated nausea and vomiting or of headache with nausea
20 following overindulgence.
5. A method for the treatment and/or prevention of migraine
which comprises administering to a patient in need of such treatment
simultaneously, separately or sequentially, an effective amount of a
25 combination of ibuprofen lysinate and domperidone or a pharmaceutically
acceptable salt thereof.
6. A method for the treatment and/or prevention of migraine-
associated nausea and vomiting or of headache with nausea following
30 overindulgence, which comprises administering to a patient in need of
such treatment, simultaneously, separately or sequentially, an effective

-9-

amount of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 99/03398

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/445 A61P25/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 34612 A (THE BOOTS COMPANY PLC) 13 August 1998 (1998-08-13) claims 1,4 page 1, line 9 -page 2, line 10 page 3, line 9-29 page 6, line 8-12	1-6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 March 2000

Date of mailing of the international search report

10/03/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 861 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/03398

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9834612 A	13-08-1998	AU 6295598 A	26-08-1998
		CZ 9902709 A	13-10-1999
		GB 2331926 A	09-06-1999
		NO 993784 A	22-09-1999
		ZA 9800968 A	06-08-1998